Invokana Lawsuit Lawyer
Attorneys for Invokana, Invokamet and other SGLT2 Claims
Hundreds of lawsuits have been filed against Johnson and Johnson’s Janssen Pharmaceuticals subsidiary, AstraZeneca and other SGLT2 manufacturers for severe side effects related to the use of SGLT2 inhibitors such as Invokana (canagliflozin). If you or a loved one has developed a serious medical condition as a result of the use of Invokana, Invokamet or another SGLT2 inhibitor used to treat type 2 diabetes, you should consult a invokana lawsuit lawyer regarding your rights today.
If you have been injured due to Invokana, Invokamet or other SGLT2 inhibitor medications, call Simmons and Fletcher, P.C. at 1-800-298-0111 to be connected with a defective drug and pharmaceutical attorney for a free consultation. You may be entitled to legal compensation.
What are Invokana and Invokamet?
Invokana (canagliflozin) is a type 2 diabetes medication that is manufactured by Johnson and Johnson. It falls under the category of medications called sodium-glucose cotransporter 2 (SGLT2) inhibitors, and it controls the body’s blood sugar by removing excess sugar through urine. Being the first drug of its class, Invokana was approved by the FDA in 2013, with a similar drug Invokamet (canagliflozin and metformin) being approved the following year. Invokana works by preventing the kidneys from reabsorbing glucose, while most type 2 diabetes medications mainly increase insulin. The drug does so by inhibiting the SGLT2 protein in the kidneys; so instead of reabsorbing sugar, the kidneys secrete it, making the sugar exit the body during urination.
Other SGLT2 Inhibitors Including Jardiance, Glyxambi, Xiigduo XR and Farxiga
Jardiance (empagliflozin) is an oral SGLT2 inhibitor manufactured and marketed by Boehringer Ingelhein. Following Jardiance’s approval in 2014, Glyxambi, a combination of Jardiance and Tradjenta, another active ingredient used to treat type 2 diabetes, was approved in 2015. Glyxambi is also created and marketed by Boehringer Ingelhein. Farxiga is manufactured by AstraZeneca and Bristol-Myers Squibb, it is a once-daily oral pill used to improve glycemic control in patients with type 2 diabetes. Farxiga, and Xigduo XR, an extended release version of Farxiga, were both approved by the FDA in 2014. Others include: Synjardy, Steglarto, Segluromet and Steglujan.
FDA Warnings for Invokana
The warning labels for Invokana and other SGLT2 inhibitors have been updated and revised by the Federal Food and Drug Administration (FDA) on many occasions since it’s release. However, if you developed a condition below prior to the date upon which proper warning was given due to SGLT2 use, you may be entitled to damages. The history of these revisions is as follows:
- On September 10, 2015, the FDA required a strengthened warning of increased risk of bone fractures and added new information about decreased bone mineral density
- On June 14, 2016, the FDA strengthened the warning label regarding the risk of acute kidney injury. Read the announcement.
- On May 16, 2017, Following two clinical trials, the FDA required the most prominent box label warning that SGLT2 use causes an increased risk of leg and foot amputations.
- On August 29, 2018, the FDA issued a warning that reports of rare cases of Fournier’s Gangrene, also called necrotizing fascitis of the perineum have been received with SGLT2 Inhibitor use.
Despite all of the above risks, SGLT2 inhibitors are still approved for use by the FDA with proper prescription.
Injuries Linked to SGLT2 Inhibitor Use
Injuries believed to be caused by the used of SGLT2 inhibitors include the following conditions:
- Fournier’s Gangrene – gangrene of the genital area.
- diabetic ketoacidosis–a serious complication that causes the body to produce excess blood acids (ketones) due to lack of insulin production,
- bone fractures,
- kidney failure,
- cardio vascular issues,
If you or a loved one suffered one of the aforementioned injuries and were prescribed an SGLT2 inhibitor prior to the dates on which the label was changed to warn of the condition, you may be entitled to make a claim for compensation.
Invokana Multidistrict Litigation (MDL) in New Jersey
More than 1,100 SGLT2 inhibitor lawsuits have been filed in state and federal courts across the nation, many of which have been consolidated in the Invokana MDL. Because the FDA added official warnings for these conditions on the various dates listed above, the statute of limitations date in your case may depend upon when you took the prescribed drug and when you first developed the condition or symptoms. You should consult a prescription drug defect attorney to determine your specific statute of limitations.
Invokana, Invokamet and other SGLT2 Attorneys
If you or a loved one has suffered ketoacidosis or other severe side effects after using Invokana, Invokamet or other SGLT2 drugs, contact Simmons and Fletcher, P.C. today. Our attorneys are passionate about helping victims discover the facts of their case so they can make an informed decision about their future. Call us today for a free consultation at 800-298-0111.
Warning: If you are experiencing symptoms of a serious side effect such as diabetic ketoacidosis or gangrene, you should seek emergency medical care at once. You should consult your physician regarding discontinuing use of any prescribed medication and/or the appearance of serious side effects.
Paul Cannon has practiced personal injury trial law since 1995. He is Board Certified in Personal Injury Trial Law (2005). He has earned recognition as a Super Lawyer by Thompson Reuters in 2017 & 2018, and as a Top 100 Trial Lawyer by the National Trial Lawyers Association in 2017. He is a Shareholder, trial lawyer and online marketing manager at Simmons and Fletcher, P.C. His legal writings have been published by the Texas Bar Journal, Business.com, Lawyer.com HG Legal Resources, Lawfirms.com, and others. He has been asked to give education talks and media interviews on dog bite law.